Effects of Tirzepatide Plus Intensive Lifestyle Therapy on Body Weight and Metabolic Health in Latinos With Obesity

NCT06009653 on ClinicalTrials.gov · last registry update 2025-02-25

Withdrawn before anyone was enrolled. The sponsor logged completion for 29 May 2024. Primary outcome, as filed: Change in body weight. tirzepatide is already approved in the US for obesity, so this is asking a further question rather than establishing the drug works at all.

Status: WITHDRAWN
Phase: P4
Drug: tirzepatide
Mounjaro, Zepbound
Sponsor: Washington University School of Medicine
Sponsor type: Other
Enrollment: 0
Started: 2023-09-13
Primary completion: 2024-05-29 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Change in body weight

Conditions studied

Obesity · Metabolic Disease

Every field above is taken directly from the registry record. See all detected changes across the class, or the tirzepatide page for this molecule’s full trial and approval history.